| 摘要: |
| 钠-葡萄糖共转运蛋白2抑制剂(Sodium-glucose cotransporter 2 inhibitors, SGLT2i)是一种良好具有心血管保护作用的新型口服降糖药物。多项研究证据表明,SGLT2i可以显著降低心力衰竭、心血管死亡的风险,并延缓慢性肾脏疾病进展。近年来临床研究发现SGLT2i可减少心律失常的发生。然而,SGLT2i对抗心律失常的作用及其发生机制尚未完全阐明。本文旨在总结从基础研究到临床报告的现有证据,以进一步探讨SGLT2i抗心律失常作用的发生机制,为心律失常防治提供新方向。 |
| 关键词: 钠-葡萄糖共转运蛋白2 抑制剂 心律失常 |
| DOI:10.13506/j.cnki.jpr.2025.10.012 |
| 基金项目:国家自然科学基金项目(No.82100485) |
|
出版日期:2025-10-25
|
|
| Research progress on antiarrhythmic effects and mechanisms of SGLT2 inhibitors |
| ZHONG Peng,ZHANG Chenghu,CAO Xiancun |
| (Department of Cardiology,Jining First People’s Hospital,Jining 272000,China) |
| Abstract: |
| Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel oral hypoglycemic agents with good cardiovascular protective effect. Multiple studies have evidenced that SGLT2i can significantly reduce the risk of heart failure, cardiovascular death, and delay the progression of chronic kidney disease. Recent studies have found that SGLT2i can reduce the occurrence and progression of arrhythmia. However, the role of SGLT-2i against arrhythmias and its exact mechanism are not fully elucidated. This paper aims to summarize the existing evidence from basic studies and clinical reports, in order to further explore the anti-arrhythmic mechanism of SGLT2i and provide a new direction for the prevention and treatment of arrhythmias. |
| Key words: Sodium-glucose cotransporter 2 Inhibitor Arrhythmology |